Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

News Daily News CRT 2021

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Michael O'Riordan

March 17, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

Meta-analysis Shows Similar 5-Year Mortality for PCI, CABG in Left Main Disease

News Daily News CRT 2020

Meta-analysis Shows Similar 5-Year Mortality for PCI, CABG in Left Main Disease

Michael O'Riordan

March 04, 2020

Good Coronary Collateral Circulation? Better LVEF and Survival After STEMI

News Conference News CRT 2020

Good Coronary Collateral Circulation? Better LVEF and Survival After STEMI

Michael O'Riordan

February 24, 2020

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

News Conference News CRT 2020

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

Michael O'Riordan

February 24, 2020

CABG vs PCI in Left Main Disease: The Debate Continues

News Conference News CRT 2019

CABG vs PCI in Left Main Disease: The Debate Continues

Yael L. Maxwell

March 12, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

News Conference News CRT 2018

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Michael O'Riordan

March 08, 2018

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

News Conference News CRT 2017

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Michael O'Riordan

February 23, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.